The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 03, 2023
Filed:
Sep. 17, 2021
Applicant:
Centaurus Therapeutics, Half Moon Bay, CA (US);
Inventors:
Donna L. Romero, Half Moon Bay, CA (US);
John M. McCall, Half Moon Bay, CA (US);
Jeremy Blitzer, Half Moon Bay, CA (US);
Assignee:
Centaurus Therapeutics, Half Moon Bay, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 31/44 (2006.01); A61K 31/167 (2006.01); A61K 31/416 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); A61P 9/10 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); C07C 233/65 (2006.01); C07D 213/73 (2006.01); C07D 231/56 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/44 (2013.01); A61K 9/0053 (2013.01); A61K 31/167 (2013.01); A61K 31/416 (2013.01); A61K 31/444 (2013.01); A61K 31/496 (2013.01); A61K 39/3955 (2013.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); C07C 233/65 (2013.01); C07D 213/73 (2013.01); C07D 231/56 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01);
Abstract
Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.